October 2026
Create an account to continue using Similarweb
View website metrics, keywords, top marketing channels, market research tools, and more.
Create your free accountijbs.com
Global Rank
#443,056
69,522Showing Similarweb estimated data.
Publicly validate your site’s metrics by connecting your GA4
Reflect your success
Verify your website's traffic and engagement metrics by connecting to Google Analytics
Bounce Rate
47.17%
Pages per Visit
2.13
Avg Visit Duration
00:00:50
- Company
- - -
- Industry
- - -
Top 10 ijbs.com Competitors
The Top 10 Sites Like ijbs.com in October 2026 are ranked by their affinity to ijbs.com in terms of keyword traffic, audience targeting, and market overlap
Nature is the foremost international weekly scientific journal in the world and is the flagship journal for Nature Portfolio. It publishes the finest ...
- Company
- nature
- Industry
- Science and Education > Biology
Bounce Rate
55.37%
Pages per Visit
2.51
Avg Visit Duration
00:03:10
Similarity Score
100%indexingmethod_automated - Search Results - PubMed
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
- -
Pages per Visit
- -
Avg Visit Duration
- -
Similarity Score
97%sciencedirect is the world's leading source for scientific, technical, and medical research. explore journals, books and articles.
Global Rank
#369
10Bounce Rate
31.28%
Pages per Visit
6.01
Avg Visit Duration
00:07:55
Similarity Score
96%providing access to millions of research articles and chapters from science, technology and medicine, and humanities and social sciences
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
62.14%
Pages per Visit
2.23
Avg Visit Duration
00:03:01
Similarity Score
92%Cerebrospinal fluid–venous fistula is an increasingly recognized cause of spontaneous intracranial hypotension.[1][1] The site of the leak is between the dural sleeve around a spinal nerve root and the surrounding foraminal veins. In appropriately investigated patients, transvenous embolization of the draining foraminal and paraspinal veins has been shown to be an effective way of treating the disease, with low periprocedural morbidity, improvement in symptoms and radiological appearances.[2][2] [Video 1][3] shows the technique employed in a typical case using Onyx (Medtronic, Minnesota, USA) to embolize a CSF–venous fistula at the right T10 neural foramen. Video 1 Video showing the technique for trans-venous embolization of a right T10 CSF-venous fistula for the treatment of spontaneous intracranial hypotension. The first section covers patient selection and work up, before then focusing on the technical aspects of navigating through the azygos system to the target foramen and completely occluding the pathway for CSF outflow. [1]: #ref-1 [2]: #ref-2 [3]: #F1
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
29.01%
Pages per Visit
2.13
Avg Visit Duration
00:00:59
Similarity Score
83%Radioimmunotherapy using 225Ac, a highly cytotoxic α-particle emitter, has potential for treating advanced breast cancer, especially human epidermal growth factor receptor 2 (HER2)–positive cases. We use a pretargeted radioimmunotherapy (PRIT) approach consisting of a 3-step intravenous regimen (step 1: bispecific anti-HER2/anti-DOTA antibody; step 2: clearing agent; step 3: 225Ac-radiolabeled Proteus DOTA, or [225Ac]Ac-Pr). Our goal was to establish curative 225Ac-PRIT with high therapeutic indices. Methods: The impact of [225Ac]Ac-Pr specific activity was evaluated in the BT-474 breast xenograft model. We tested the effects of [225Ac]Ac-Pr dosing during PRIT on tumor-targeting efficiency and tissue biodistribution. Using a 225Ac-PRIT regimen consisting of a ratio of 1.19 nmol of bispecific antibody to 0.60–0.66 nmol of [225Ac]Ac-Pr, we evaluated therapy in the BT-474 model and a patient-derived xenograft model. BT-474-tumor–bearing mice were treated with 1 or 2 cycles of 225Ac-PRIT (37 kBq/cycle) separated by 1 wk. A dose escalation study was performed on the BT-474 model to establish an absorbed radiation dose of approximately 40 Gy (relative biological effectiveness [RBE], 5) as a nephrotoxic dose, as no such histologic findings were observed in prior studies at the 20.7-Gy (RBE, 5) renal dose level. Results: In the BT-474 model, 100% (20/20) achieved complete responses and histologic cure in 17 of 20 (85%) of the treated animals. One-cycle and 2-cycle treatments were equally effective. Treatments were well tolerated, with no chronic radiation toxicity documented during necropsy at 175 d. Dosimetry estimates (RBE, 5) per 37 kBq administered for tumors and kidneys were 210 and 3.5 Gy, respectively. In the patient-derived xenograft model, a single 225Ac-PRIT treatment led to 60% (3/5) complete response and prolonged survival (>93 d) versus no treatment (30 d; P = 0.0185). Lastly, a 225Ac-PRIT regimen was identified that induces severe chronic nephrotoxicity (41.4
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
56.36%
Pages per Visit
2.04
Avg Visit Duration
00:01:23
Similarity Score
82%- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
67.86%
Pages per Visit
1.47
Avg Visit Duration
00:00:06
Similarity Score
80%Discover and read the most cited articles from BMJ Quality & Safety published over the past two years.
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
59.32%
Pages per Visit
2.28
Avg Visit Duration
00:01:19
Similarity Score
79%Oncology On the Go With ASTCT Talks | Podcasts | CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
- Company
- CancerNetwork
- Industry
- Health > Health - Other
Global Rank
#361,747
43,867Bounce Rate
45.98%
Pages per Visit
1.59
Avg Visit Duration
00:00:35
Similarity Score
78%- Company
- - -
- Industry
- - -
Global Rank
#325,519
1,594Bounce Rate
52.85%
Pages per Visit
1.56
Avg Visit Duration
00:00:48
Similarity Score
77%ijbs.com's top 5 competitors in October 2026 are: nature.com, pubmed.ncbi.nlm.nih.gov, sciencedirect.com, link.springer.com, and more.
According to Similarweb data of monthly visits, ijbs.com’s top competitor in October 2026 is nature.com. ijbs.com 2nd most similar site is pubmed.ncbi.nlm.nih.gov, and closing off the top 3 is sciencedirect.com.
link.springer.com ranks as the 4th most similar website to ijbs.com and jnis.bmj.com ranks fifth in October 2026.
The other five competitors in the top 10 list are jnm.snmjournals.org, n.neurology.org, qualitysafety.bmj.com, cancernetwork.com, and contemporaryobgyn.net.